

Camila R Fontes-Garfias

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9595630/publications.pdf>

Version: 2024-02-01

22
papers

9,682
citations

471371

17
h-index

552653

26
g-index

32
all docs

32
docs citations

32
times ranked

16827
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	13.9	2,107
2	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. <i>Nature</i> , 2020, 586, 594-599.	13.7	1,520
3	Spike mutation D614G alters SARS-CoV-2 fitness. <i>Nature</i> , 2021, 592, 116-121.	13.7	1,380
4	Phase III study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	13.7	1,197
5	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. <i>Nature</i> , 2021, 595, 572-577.	13.7	583
6	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. <i>Nature Medicine</i> , 2021, 27, 620-621.	15.2	562
7	Neutralizing Activity of BNT162b2-Elicited Serum. <i>New England Journal of Medicine</i> , 2021, 384, 1466-1468.	13.9	528
8	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	13.7	494
9	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. <i>Nature Communications</i> , 2020, 11, 4059.	5.8	266
10	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. <i>Nature Communications</i> , 2020, 11, 5214.	5.8	179
11	3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk. <i>Nature Genetics</i> , 2018, 50, 783-789.	9.4	148
12	Functional Analysis of Glycosylation of Zika Virus Envelope Protein. <i>Cell Reports</i> , 2017, 21, 1180-1190.	2.9	118
13	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. <i>New England Journal of Medicine</i> , 2021, 385, 472-474.	13.9	93
14	A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20190-20197.	3.3	53
15	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. <i>JCI Insight</i> , 2021, 6, .	2.3	46
16	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. <i>Npj Vaccines</i> , 2021, 6, 44.	2.9	36
17	A Zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity. <i>Cell Reports</i> , 2022, 39, 110655.	2.9	20
18	An attenuated Zika virus NS4B protein mutant is a potent inducer of antiviral immune responses. <i>Npj Vaccines</i> , 2019, 4, 48.	2.9	14

#	ARTICLE	IF	CITATIONS
19	Evaluation of a SARS-CoV-2 lateral flow assay using the plaque reduction neutralization test. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115248.	0.8	13
20	Genetic stability of live-attenuated Zika vaccine candidates. <i>Antiviral Research</i> , 2019, 171, 104596.	1.9	6
21	A genetically stable Zika virus vaccine candidate protects mice against virus infection and vertical transmission. <i>Npj Vaccines</i> , 2021, 6, 27.	2.9	5
22	Reverse genetic approaches for the development of Zika vaccines and therapeutics. <i>Current Opinion in Virology</i> , 2020, 44, 7-15.	2.6	3